Century Therapeutics, Inc. 8-K

What Happened
Century Therapeutics, Inc. filed an 8-K (dated June 16, 2026) reporting that on June 15, 2026 the company entered into an Amended and Restated Employment Agreement with Chad Cowan, Ph.D., its Chief Scientific Officer. Under the new A&R Agreement, Dr. Cowan will continue in the CSO role on a part‑time basis with a reduced annual base salary of $296,150 and remain eligible for an annual performance‑based target bonus on a pro‑rated basis. The full A&R Agreement will be filed as an exhibit to the company’s Form 10‑Q for the quarter ended June 30, 2026.

Key Details

• Agreement date: June 15, 2026; 8‑K filed June 16, 2026.
• New base salary: $296,150 per year (part‑time).
• Bonus: Eligible for annual performance‑based target bonus, paid on a pro‑rated basis.
• Termination/resignation: Dr. Cowan is entitled to accrued and unpaid base salary through the cessation date.
• The A&R Agreement will be attached as an exhibit to the June 30, 2026 Form 10‑Q.

Why It Matters
This 8‑K documents an executive compensation and role change for Century’s head of scientific development—important for investors tracking leadership continuity and operating costs. The amendment formalizes a move to part‑time status with a lower salary and pro‑rated bonus, and the full agreement will be available in the upcoming 10‑Q for anyone needing the complete terms.